2. >>Products
  3. >>Biosimilars

Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales

As Company Plans To Launch One Biological Product Every Year

 
• By Akriti Seth

South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year. 

Winning
Celltrion saw double-digit growth in Q4 FY21 • Source: Alamy

Celltrion has reported achieving “a record-high revenue” of KRW605.8bn ($490m) for the fourth quarter ending 31 December 2021, compared to KRW387bn reported in Q4 FY20. The South Korean company credited the revenue growth to the increased sales of Remsima/Inflectra (infliximab) and the contribution from its Regkirona COVID-19 treatment, more than offsetting a sales decrease for Truxima (rituximab) in the profitable North America market.

Celltrion claims to have the most prescribed infliximab drug in Europe, while it continues to expand prescriptions in Japan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products